SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (177)2/10/2000 6:27:00 PM
From: Pierre Borczuk  Read Replies (1) | Respond to of 370
 
Have been following VION for years now...who would have though it would break 15

Pierre



To: Jim Oravetz who wrote (177)2/25/2000 1:11:00 PM
From: Jim Oravetz  Read Replies (2) | Respond to of 370
 
A group including Elliott Associates L.P. reduced its stake in Vion Pharmaceuticals Inc. (VION) to 14.8%.
In a filing Tuesday with the Securities and Exchange Commission, the group said it sold 103,700 common shares between Feb. 15 and Feb. 22 at prices ranging from $14.54 and $16.05 a share, and currently holds 1.49 million shares of the New Haven, Conn., biopharmaceutical company

Jim


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News